Tuberculosis (TB) is one of the most important public health problems, with eight million new cases and 1.4 million deaths reported each year ([@B42]). In 2008, the World Health Organization (WHO) reported a considerable increase in multidrug-resistant TB (MDR-TB) cases ([@B19]); this situation was even more dramatic in regions with a high rate of human immunodeficiency virus (HIV) infection ([@B26]). The emergence and spread of these isolates, particularly the extensively drug-resistant isolates TB, is a serious problem for TB control programs. The problem is particularly serious in developing countries, where only 8.5% of MDR-TB cases are diagnosed and an even lower proportion of cases have access to appropriate treatment ([@B41]). Several other factors are responsible for this global TB scenario, of which most are related to economic and social issues, such as poverty, drug addiction and a lack of access to health programs ([@B40], [@B31]). While approximately 14% of new TB cases worldwide are MDR, this number can reach up to 50% among previously treated patients and in certain regions ([@B43]). In developing nations, drug susceptibility testing (DST) is still carried out using phenotypic methods. The most common phenotypic method, a culture on Löwenstein-Jensen (LJ) solid medium, is an inexpensive and relatively simple procedure; however, it requires trained workers and the results are not available until several weeks after the primary culture ([@B25]). Therefore, there is a need for accurate and low-cost diagnostic assays for both drug-susceptible and drug-resistant TB. In the case of rifampicin (RMP), approximately 95% of the *Mycobacterium tuberculosis* isolates ([@B8], [@B12]) are resistant (RMP-R) due to single nucleotide polymorphisms (SNPs), which are small deletions or insertions primarily within an 81 bp region of the *rpo*B gene and are mainly found in codons 531, 526 and 516 ([@B44], [@B15]).

Isoniazid resistance (INH-R) is more complex and is associated with mutations in one or more genes, such as the genes encoding catalase-peroxidase \[*katG* gene (codon 315)\] and the enoyl-acyl-carrier protein reductase enzyme, which is involved in mycolic acid biosynthesis \[*inhA* (-15 nucleotide)\] ([@B39]). Commercial methods based on genotyping are available for the simultaneous identification of *Mycobacterium* at the species level and the detection of resistance to the primary ﬁrst-line drugs, such as GeneXpert ([@B13]) and GenoType MTBDR*plus* (Hain Lifesciences) ([@B18]), for detecting RMP-R and INH-R, respectively. However, the phenotypic or genotypic characterisation of every *M. tuberculosis* isolate or sputum sample containing acid-fast bacilli is currently time consuming, costly and feasible only in low TB burden countries; it is not feasible in the developing countries where TB and MDR-TB are of major concern ([@B31]). Therefore, in 2010, the WHO recommended that new rapid diagnostic methods be developed to help prevent TB transmission, especially the transmission of resistant bacilli ([@B42]).

The goal of the present study was to develop a molecular assay based on the reverse hybridisation of membranes with rapid detection of the mutations that are most frequently related to RMP-R and INH-R *M. tuberculosis*. Direct polymerase chain reaction (PCR) sequencing and GenoType MTBDR*plus* were used as the reference methods and were performed on the same set of samples.

MATERIALS AND METHODS
=====================

*Cultures, susceptibility testing and DNA extraction* - One hundred and eight cultures had previously been tested for drug susceptibility using the Ogawa-Kudoh standard proportion method ([@B9]) at the Central Laboratory of Rio Grande do Sul (IPB/LACEN-RS), the regional reference laboratory for *Mycobacterium*-related disease in the city of Porto Alegre, South Region of Brazil. This study was approved by the Ethical Committee of the School of Public Health and the State Foundation of Health Research and Production of Brazil under protocols 465/09 and 03/2010, respectively.

Nucleic acids were extracted from the *M. tuberculosis* culture using the cetyl trimethylammonium bromide method, as described previously ([@B37]) at the Centre of Scientific and Technological Development of the State Foundation in Production and Health Research, Porto Alegre. The genes encoding *rpo*B, *kat*G and the *inh*A promoter, which are related to RMP and INH, respectively, had been sequenced as part of an earlier study ([@B38], [@B23]). The H37Rv (ATCC27294) reference strain was used as a control for both DST and genotyping.

*Amplification of part of rpoB, katG, inhA and IS6110* - The multiplex PCR was performed using the primers described in Supplementary data. The reverse primers were biotin labelled and the PCR-multiplex was standardised in a final volume of 50 µL containing 200 µM of each dNTP, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM MgCl~2,~10 pmoles of primers Rif1 and Rif2 each, 25 pmoles of primers *kat*G1 and *kat*G2, *inh*A1 and *inh*A2 and IS1 and IS2 each, 2.5 U of Taq DNA polymerase (Invitrogen/USA) and 1 µL (100 ng/µL) of purified bacterial DNA. The PCR reactions were carried out as follows: 3 min at 95ºC, 30 cycles of 1 min at 95ºC, 1 min at 60ºC, 1.5 min at 72ºC and 4 min at 72ºC. Each amplification experiment included a positive (*M. tuberculosis*H37Rv DNA, 100 ng) and a negative control (water). For standardisation of the amplification reactions, the PCR products were analysed using polyacrylamide gel electrophoresis, followed by detection in ultraviolet light after staining with ethidium bromide and comparison of the amplicons to a molecular weight marker.

*Reverse-line blot hybridisation and colorimetric detection* - Reverse hybridisation and colorimetric detection were performed based on the previously described protocol ([@B23], [@B24]), with some modifications. The membranes were washed in 2x SSC/0.1% sodium dodecyl sulfate (SDS) for 5 min at 50ºC and were incubated in 2x SSC with 5% bovine serum albumin (BSA) at 50ºC for 15 min. Twenty-five microlitres of each PCR reaction was added to 150 μL of 2x SSC/0.1% SDS and the mixture was denatured at 100ºC for 10 min and then transferred to an ice bath. The denatured PCR product was then added to a polyethylene tube containing a membrane in 1.4 mL of the hybridisation solution (2x SSC/0.1% SDS). Hybridisation was achieved by incubation at 62ºC for 30 min. After hybridisation, the membranes were washed in 2x SSC/0.5% SDS at 57ºC for 10 min each. The membranes were then treated with Tris-buffered saline (TBS) (100 mM Tris-HCl, 150 mM NaCl, pH 7.5) containing 6% BSA for 30 min at 50ºC. The membranes were incubated in TBS containing 0.33 μg/mL streptavidin-alkaline phosphatase (AP) conjugate for 15 min at room temperature (RT). The unbound conjugate was removed by washing in TBS for 10 min followed by the addition of AP buffer (100 mM Tris-HCl, 150 mM NaCl and 5 mM MgCl~2~·6H~2~O, pH 9.5) for 10 min at RT. The hybridisation was visualised by adding 40 μg/mL 5-bromo-4-chloro-3-indoyl phosphatase and 82.5 μg/mL nitro blue tetrazolium (Sigma) in the AP buffer and incubation for 10 min at RT. A purple precipitate was observed when there was a perfect match between the probe and the biotinylated PCR product. The colorimetric reaction was blocked with distilled water and the membranes were dried at RT.

*Sensitivity and specificity of the assay* - The analytical sensitivity of the test was determined by performing the assay with a serial 10-fold dilution of *M. tuberculosis*H37Rv DNA (100 ng to 1 pg). To determine the specificity of LINE-TB/MDR, 100 ng of genomic DNA from each of the following bacteria were submitted to the entire procedure: *Neisseria meningitidis, Streptococcus pneumoniae, Salmonella enterica, Haemophilus influenzae, Escherichia coli* (obtained from IPB/LACEN-RS), *Mycobacterium marinum, Mycobacterium intracellulare, Mycobacterium scrofulaceum, Mycobacterium gordonae, Mycobacterium avium, Mycobacterium smegmatis, Mycobacterium kansasii, Mycobacterium xenopi, Mycobacterium fortuitum-peregrinum*and *Mycobacterium phlei*(obtained from Oswaldo Cruz Foundation, Brazil) ([@B38], [@B23]).

*Probe design and binding to membrane* - The oligonucleotide probes were designed using the Software Primer express v.2.0 (Applied Biosystems). Our final assay setup was composed of (i) five probes for the wild type (WT) *rpo*B allele and five probes for each of the different *rpo*B mutant alleles, (ii) one probe each for the WT and mutant *kat*G and (iii) one probe each for the WT and mutant *inh*A promoter alleles. Additionally, we designed a probe specific for hybridisation with the insertion sequence IS*6110* (Supplementary data).

For the immobilisation of the DNA probes, a negatively-charged nylon membrane (Biodyne C, Pall Corporation) was activated in a solution of 16% (w/v) (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) (Acros Organics) for 20 min at RT and was washed in distilled water for 2 min at RT. Then, 10 μL of each of the oligonucleotide probes, containing a 5'-terminal amino group, were diluted to the appropriate concentration (Supplementary data) in 0.5 M NaHCO~3~(pH 8.4) and plotted into 15 circles (5 mm) previously designed on the membrane, followed by incubation for 1 min at RT. The membranes were then incubated in 0.1 M NaOH for 10 min, washed in distilled water for 2 min at RT, washed in 2x SSC/0.1% SDS for 10 min at 50ºC and finally incubated in 20 mM EDTA (pH 8.0) for 15 min at RT. The membranes were finally transferred into a polyethylene tube and stored at 4ºC for later use.

*Assay interpretation* - The panel F in [Figure](#f01){ref-type="fig"} demonstrates the positions of the probes for *rpo*B, *kat*G, *inh*A and IS*6110*. A hybridisation result was considered positive when a purple colour was observed in the circle where a particular probe had been plotted. The probes in *rpo*B were located within the 81 bp resistance-determining region (RDR) and hybridisation with all five WT probes was considered to indicate an RMP-susceptible strain. When one of these signals was lacking, independent of any hybridisation to probes 6-10, the strain was considered to be an *rpo*B-mutated strain. A strain was considered mutated for the *inhA* gene when there was a lack of hybridisation to probe 12 and/or hybridisation to probe 11 occurred; the WT *kat*G gene was represented by hybridisation to probe 13 and a positive signal for probe 14 was observed when the gene was mutated. The hybridisation to probe 15 (IS*6110*) was an additional confirmation of the *M. tuberculosis*complex (MTBC).

A: example of the wild type (WT) result to the three genes *rpo*B, *kat*G and *inh*A; B: example of a strain mutated in the 531 region of the *rpo*B gene with no hybridisation with the Rif5wt probe and hybridisation with the Rif4M; C: hybridisation with the 14 *kat*GM probe; D: hybridisation with the probe number 11; E: hybridisation was not observed with the rif4 probe, what suggested that there are mutation in the *rpo*B gene codon 526, although the method have not allowed to identified the mutation; F: schematic presentation of LINE-TB/MDR. Probes position: *rpo*B WT probes, circles 1-5 (Rif 1, Rif 2, Rif 3, Rif 4, Rif 5); *rpo*B mutated probes, 6-10 (Rif1M, Rif2M, Rif3M, Rif4M, Rif5M); 11, *inh*AM; 12,*inh*A*wt*; 13, *katG*wt; 14, *katG*M; 15, IS*6110*.

*GenoType* ^*®*^ *MTBDRplus assay* - The GenoType MTBDR*plus* assay was performed according to the manufacturer's instructions ([@B12]). Of the 108 previously selected samples, 65 were tested using the GenoType MTBDR*plus* assay. In order to guarantee the highest fidelity possible between the LINE-TB/MDR assay and the GenoType MTBDR*plus* assay, the same DNA aliquot was used in both experiments.

RESULTS
=======

A positive hybridisation signal was observed with the probe specific for IS*6110* for all 108 isolates; no non-mycobacterial DNAs or *Mycobacterium*species other than those of the MTBC presented a signal at this membrane region. The test was therefore 100% sensitive and specific for strains belonging to the MTBC (A in [Figure](#f01){ref-type="fig"}). Among the 108 cultures, 55 were considered sensitive to both of the drugs and presented the WT alleles for *rpo*B, *kat*G and *inh*A in the DST. Sequence analysis demonstrated the presence of at least one mutation in the *rpo*B gene in 53 of the MDR-TB samples and among these, 31 presented an additional mutation in *kat*G. There were also three samples that presented mutations in the *inh*A promoter region and 10 presented mutations in both *kat*G and *inh*A. Nine isolates (17%) had no mutation in either of the INH-R-associated genes ([Table I](#t01){ref-type="table"}).

TABLE ICorrelation between LINE-TB/MDR and sequencingLINE-TB/MDR pattern  LINE-TB/MDR result-location of mutationSequencing data  Positive probesGene (probe) Nucleotide/amino acid changesStrains n (%)1,2,3,4\**rpoB (Rif4M)*S531LTCG-TTG/Ser-Leu37 (69.8)1,2,3,4\**rpo*B (Rif5M)S531WTCG-TGG/Ser-Trp1 (1.88)1,2,4,5\**rpo*B (Rif3M)H526DCAC-GAC/His-Asp4 (7.5)1,3,4,5\**rpo*B (Rif2M)H526YCAC-TAC/His-Tyr4 (7.5)1,2,3,5\*Lack hybridisationH526LCAC-GTC/His-Leu1 (1.88)1,2,3,5\*Lack hybridisation at (Rif2/3M)H526RCAC-CGC/His-Arg1 (1.88)1,2,3,5\*Lack hybridisation at (Rif2/3M)H526PCAC-CCC/His-Pro1 (1.88)1,2,3,5\*Lack hybridisation at (Rif2/3M)H526LCAC-CTC/His-Leu1 (1.88)1,3,4,5\*Lack hybridisation at (Rif2/3M)D516YGAC-TAC/Asp-Tyr2 (3.77)1,3,4,5\**rpo*B (Rif1M)D516VGAC-GTC/Asp-Val1 (1.88)11\**inh*A*(inhAM)*-15C-T13 (24.6)12\**inh*A (inhAwt)No mutationWT40 (75.4)14\**Kat*G*(katGM)*S315TAGC-ACC/Ser-Thr41 (77.3)13\**kat*g (katGwt)No mutationWT12 (22.7)1,2,3,4,5,12,14\*WTNo mutationWT55 (100)WT: wild type.

The LINE-TB/MDR method achieved 100% sensitivity (55/55) among the WT samples and, as such, identified the INH-S and RMP-S isolates; this was demonstrated by hybridisation to the five WT *rpoB* probes (probes 1-5) and the WT *inh*A and *kat*G probes (probes 12 and 13) (A in [Figure](#f01){ref-type="fig"}).

Among the 53 MDR strains, 38 had a mutation in codon 531. The LINE-TB/MDR assay was able to correctly identify all of the mutations occurring at codon 531 when the SNP involved resulted in an amino acid (aa) change of Ser→Leu; these strains exhibited hybridisation signals with probes 1 through 4 and 9, but had a lack of hybridisation to probe five (B in [Figure](#f01){ref-type="fig"}). Among the 12 additional isolates with *rpoB* mutations, the LINE-TB/MDR method correctly identified eight codon 526 mutants, of which four presented a His→Asp aa change and four presented a His→Tyr aa change. Codon 516 in the LINE-TB/MDR assay correctly identified a single strain that had the Asp→Val aa change. Four mutants at codon 526 and two mutants at codon 516 did not have a complementary mutant probe in our assay, but they lacked hybridisation signals with the WT 526 probe 4, as expected, and probe 2, which represented the WT codon 516 (E in [Figure](#f01){ref-type="fig"}). The comparison of the results obtained for all of the isolates using the LINE-TB/MDR assay (n = 108) and the *rpoB* RDR sequencing as a reference is summarised in [Table II](#t02){ref-type="table"}. This assay reported a Kappa value (k) \[95% confidence interval (CI)\] and agreement of 1 (99.5-100.0).

TABLE IIComparison of the results obtained for the identification of mutation with the sequencing and with drug susceptibility testing (DST) Results   Compared results    (n = 108)(n = 108)   LINE-TB/MDRLINE-TB/MDRLINE-TB/MDRLINE-TB/MDRKappa SESP LINE-TB/MDRSeqwt/Seq wtmut/Seq wtwt/Seq mutmut/Seq mut(95% CI)p(%)(%)INH wt586458334488.9 (82.5-95.2)\< 0.00177.690.6INH res5044RMP wt5555550053100 (99.5-100.0)\< 0.001100100RMP res5353 LINE-TB/MDR LINE-TB/MDRLINE-TB/MDRLINE-TB/MDRLINE-TB/MDRKappa SESP  DSTwt/DST-Smut/DST-Swt/DST-Rmut/DST-R(95% CI)p(%)(%)INH wt5555  55  0124188.7 (82.2-95.1)\< 0.00177100INH res4153   RMP wt5555550053100 (99.5-100.0)\< 0.001100100RMP res5353   CI: confidence interval; INH: isoniazid; RMP: rifampicin; SE: sensitivities; SP: specificities.

We also evaluated the performance of the LINE-TB/MDR method in 53 INH-resistant isolates. According to the sequence data, 44 of these isolates carried mutations in *katG* and/or *inhA*and 41 (77.3%) were *katG* 315 (AGC-ACC) (Ser→Thr). Among these samples, the LINE-TB/MDR method was able to correctly identify 36 (88%), with a positive signal at probe 14 (*katG*M) and a lack of hybridisation at probe 13 (*kat*GWT) (C in [Figure](#f01){ref-type="fig"}). Three isolates with a mutation in codon 315 gave a positive signal for probe 13 (*kat*GWT), while two of the isolates did not hybridise to any of the *kat*G probes (E in [Figure](#f01){ref-type="fig"}). Among the 12 isolates, 11 (91.6%) hybridised to probe 13 (*katG*WT), as expected, but one isolate again failed to hybridise to any of the *kat*G probes. In addition, 40 of the 53 MDR strains (75.4%) presented a WT*inhA* genotype; among these, 37 (92.5%) showed hybridisation to probe 12 (*inhA*WT) and a lack of hybridisation to probe 11 (*inhA*M) (D in [Figure](#f01){ref-type="fig"}). Three isolates presented discordant results when compared to the sequencing data; one sample hybridised to probe 11, corresponding to a mutated region of the gene (*inhA*M), while two isolates did not hybridise to any of the inhA probes (*inhA*M). The other strains (n = 13; 25%) contained the mutation C-15T in the promoter region of *inhA*and 10 (77%) strains correctly demonstrated hybridisation to probe 11 (*inhA*M), while three failed to hybridise to either probe 11 or 12. In conclusion, the overall results of the LINE-TB/MDR assay (n = 108) and the combined sequences of *kat*G and*inh*A demonstrated a k (95% CI) of 0.889 (82.5-95.2) for *kat*G and*inh*A and an negative predictive value and positive predictive value of 94.8% and 100%, respectively ([Table II](#t02){ref-type="table"}).

Sixty-five of the 108 isolates were also analysed using the GenoType MTBDR*plus* assay and 25 susceptible strains with WT, INH and RMP sequences were correctly identified. Among the 40 RIF-resistant strains that also had RMP-R genotypes, 37 (92.5%) were recognised correctly by MTBDR*plus*, while three were identified as WT strains. The concordance rates between the LINE-TB/MDR and MTBDR*plus* assays for drug resistance (DR) detection in these samples were 93.6% (63/65) for the INH sequences and 87.4% (62/65) for the RMP sequences ([Table III](#t03){ref-type="table"}). The MTBDR*plus* did not identify three RMP-R strains that were correctly identified by LINE-TB/MDR and sequencing and three sequencing-confirmed INH-R isolates were not identified by LINE-TB/MDR.

TABLE IIIComparison of the results obtained for the identification of GenoType MTBDR*plus* with the sequencing and with LINE-TB/MDR ResultsCompared results (n = 65)(n = 65) Hain strip Hain stripHain stripHain stripHain stripKappa SESP  Seqwt/Seq wtmut/Seq wtwt/Seq mutmut/Seq mut(95% CI)p(%)(%)INH wt272525324096.9\< 0.00187.0100.0INH res3840(89.9-98.6)RMP wt282525033790.5\< 0.00192.5100.0RMP res3740(84.3-86.4)   Hain stripHain stripHain stripHain stripKappa    Hain stripLINE-TB/MDRwt/LINE-TB/MDR wtmut/LINE-TB/MDR wtwt/LINE-TB/MDR mutmut/LINE-TB/MDR mut(95% CI)p  INH wt252525023893.6\< 0.001  INH res4040(86.7-97.5)   RMP wt282525033787.4\< 0.001  RMP res3740(84.3-96.2)   CI: confidence interval; INH: isoniazid; RMP: rifampicin; SE: sensitivities; SP: specificities.

DISCUSSION
==========

MDR-TB is defined by simultaneous resistance to INH and RMP, the main drugs used for TB treatment ([@B16]). Because *M. tuberculosis* is a clonal organism, most of the acquisition of DR in *M. tuberculosis* is due to point mutations in the chromosome ([@B35], [@B29]) that accumulate and are preserved in the different lineages ([@B6], [@B34]). These traits of *Mycobacterium* render it suitable for the development of assays for the detection and eventual characterisation of the presence of well-described INH-R and RMP-R SNPs ([@B10], [@B3], [@B8]). In Brazil, as recommended by the Ministry of Health, TB diagnosis and DST can be performed using solid media (LJ or Ogawa-Kudoh) and liquid media (Middlebrook 7H10), but these methods have several limitations, mainly related to the delay of diagnosis, which can be as long as 12 weeks ([@B25]). For DR detection, tests based on reverse blot hybridisation probes, such as the Line Probe Assay (INNO-LiPA assay Rif TB, Innogenetics) and the GenoType MTBDR*plus* assay, are currently widely used in many countries. These tests have sensitivities ranging from 71-100% and specificities of 96-100% ([@B7], [@B1]). While INNO-LiPA is restricted to the identification of RMP resistance, GenoType is able to identify both RMP and INH resistance. However, both of these methods are expensive and not widely available in developing countries ([@B20], [@B22]). Recently, a molecular test for the detection of *M. tuberculosis* and mutations conferring RMP resistance directly from sputum (GeneXpert, Cepheid Sunnyvale, CA, USA) was developed, but the performance characteristics of this procedure might be different when implemented in environments with low or high TB burdens ([@B13], [@B17]). For the evaluation of our reverse hybridisation-based assay for the detection of RMP-R and INH-R, we chose a panel of strains with mutations similar to those reported in other publications. The mutations were predominantly localised in codons 531, 526 and 516 of the *rpo*B gene ([@B32]) in codon 315 of the *kat*G gene ([@B30], [@B2]) and at position -15 of the *inh*A regulatory region ([@B27]). All of the 108 isolates analysed by LINE-TB/MDR showed specific hybridisation to the IS*6110*probe, which was used for *M. tuberculosis*identification (amongst other members of the MTBC), indicating that this method can be a reliable tool for TB diagnosis. This result is similar to that found previously by our research group when testing a method to detect TB (DETEC-TB) ([@B24]). In addition, the 55 DNA samples that did not contain mutations in the genes associated with resistance and were drug susceptible according to the DST, were correctly identified by the LINE-TB/MDR method. Of the 53 samples with mutations in the *rpoB* gene, 100% (53/53) hybridised to at least one *rpoB*-mutated probe or showed no hybridisation to the WT probe, confirming that the isolate was not susceptible to RMP; there was complete agreement (k = 1) between the current test and the sequencing results ([Table II](#t02){ref-type="table"}). These data suggest that the LINE-TB/MDR method can be used to reliably detect resistance to this drug, as observed by [@B4], when using a commercial kit and samples, both mutated or not, in the *rpo*B gene. When SNPs for which a mutant probe was developed were present, we observed a corresponding signal for that mutant and a lack of hybridisation to the WT probe. Four isolates carried SNPs that had no mutant probe represented and, as expected, demonstrated a lack of signal in the WT probe only (E in [Figure](#f01){ref-type="fig"}), which indicated the presence of an SNP associated with RMP-R. The sensitivity for detecting RMP resistance was 100%, with sequencing used as the reference method. This is promising for the rapid detection of MDR/TB isolates because RMP mono-resistant isolates are rarely observed ([@B21]). Previous studies reported that approximately 95-100% of RMP-resistant clinical isolates carry mutations in an 81 bp region of the *rpo*B gene ([@B27]). Therefore, in cases with a lack of SNPs in this region, we do not expect our assay to be useful for detecting RMP-R. Although most of the methods used to detect mutations related to INH resistance use only the *kat*G gene as a target, [@B23] demonstrated that the concomitant evaluation of *kat*G and the *inh*A regulatory region improves sensitivity for identifying INH resistance ([@B4]). In this study, only three INH-resistant isolates had mutations in the *inh*A gene, but the frequency of INH-resistant isolates containing the SNP (C→G) at position 315 of *katG*(Ser→Thr) ranged from 50-100% in the literature, including literature from Brazil ([@B14], [@B11]). This aa change seems to lead to a decrease in catalase peroxidase enzyme activity, which has been described as essential for the activation of the drug ([@B45], [@B32]). When the LINE-TB/MDR method was compared to DST, which is a reference for MDR/TB identification, the overall agreement was 88.7% (82.2-95.1). Among the 12 DNA samples that were not correctly identified as INH-resistant, nine were found to have an *inhA*and *katG* WT genotype by sequencing even though they were identified as MDR by DST; only three showed no hybridisation to the probes used in our assay. Some studies report that approximately 10-30% of INH-R *M. tuberculosis* strains have no mutations in DR-associated genes ([@B14]) and may have other resistance mechanisms, such as efflux pumps or cell envelope permeability ([@B20]). The prevalence of *kat*G and *inh*A mutations, as well the frequency and type of gene mutations, varies greatly among different geographic regions, with ranges of 35-91% and 20-35%, respectively ([@B28], [@B33], [@B11]). The inclusion of other genes, such as the *oxyR-ahpC*intergenic region, may increase the sensitivity of the test, although the relationship between INH resistance and mutations in this region are not yet fully understood. In previous work, mutations in this gene have frequently been observed to be associated with mutations in other genes and have been found alone in very few isolates ([@B11]).

The LINE-TB/MDR method achieved satisfactory results for the identification of SNPs involved in INH resistance, with a sensitivity of 91.6% (99/108), which is similar to the performance of GenoType MTBDR*plus* and other commercial kits ([@B5], [@B18]). Our aim was to evaluate the potential contribution of a new "in-house" test for accelerating the laboratory detection of RIF and INH resistant strains, particularly when MDR-TB is suspected.

The discrepancies between the LINE-TB/MDR method and DNA sequencing might be due to (i) the specificity of the probes, (ii) the analysis of hetero-resistant strains or (iii) the lack of sensitivity of the hybridisation. It should be noted that the LINE-TB/MDR test identified three isolates as INH-resistant using *inhA*M probe hybridisation, while the sequencing data identified them as WT*inh*A. This could be due to the higher sensitivity of the hybridisation-based assays compared to sequencing-based assays for detecting mixed bacterial populations ([@B36]) and this issue is currently under investigation.

In summary, the LINE-TB/MDR method described in this study offers advantages over alternative techniques and provides results 6 h after amplification of the target, considerably decreasing the time needed for DST. We are now in a second-phase trial for the evaluation of the reproducibility of this test in different laboratories. The hope is that this test will be an additional tool for the diagnosis of MDR-TB and will be routinely applied in laboratories in regions with high TB and TB/HIV burdens and limited financial resources.

Supplemntary data
=================

Probe set for identification of the wild type (WT) and mutant genotypes SequenceLength Probes concentrationProbes(5\'-3\')(bp) (pmolμL)Rif1wtCAGCCAGCTGAGCCAATTCAT21WT5.0Rif2wtTTCATGGACCAGAACAACCC20WT10.0Rif3wtCGCTGTCGGGGTTGACC17WT10.0Rif4wtTTGACCCACAAGCGCCGACT20WT5.0Rif5wtCTGTCGGCGCTGGGGC16WT10.0Rif1MCCAATTCATGGTCCAGAA21Mutant5.0Rif2MGTTGACCTACAAGCGCCG18Mutant10.0Rif3MGGTTGACCGACAAGCGCC18Mutant10.0Rif4MCTGTTGGCGCTGGGGC16Mutant10.0Rif5MCGACTGTGGGCGCTGG16Mutant10.0*katG* wtTCACCAGCGGCATCGAG17WT0.4katGMTCACCACCGGCATCGAG17Mutant0.4inhAwtCGGCGAGACGATAGGTTGTC20WT0.6IS6110TGCCCGTCCCGCCGATCTC18WT1.0

Primers used for amplification and standardisation of multiplex PCR for genes rpoB, katG, inhA and IS6110  SizeGenePrimer sequence (5\'-3\')(bp)IS6110IS1 CGTGAGGGCATCGAGGTGGC245 IS2 Bio-GCGTAGGCGTCGGTGACAAA rpoBRif1 GGTCGCCGCGATCAAGGAGT157 Rif2 Bio-TGCACGTCGCGGACCTCCA katGkatG1 CATGAACGACGTCGAAACAG232 katG2 Bio-CGAGGAAACTGTTGTCCCAT inhAinhA1 CCTCGCTGCCCAGAAAGGGA248 inhA2 Bio-ATCCCCCGGTTTCCTCCGGT 

To all patients and their families.
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